InvaGen Agrees To Admit Infringing Diabetes Drug To End Suit

Law360 (June 7, 2019, 8:40 PM EDT) -- Pharmaceutical companies Mitsubishi Tanabe Pharma Corp., Janssen Pharmaceuticals Inc. and Cilag GmbH International have asked a New Jersey federal judge to sign off on their deal to drop a patent infringement lawsuit against InvaGen Pharmaceuticals Inc. over its application for the generic version of Janssen's diabetes treatment Invokamet.

The trio agreed to dismiss with prejudice the allegations against InvaGen after it agreed to admit infringing a patent for Invokamet by attempting to get approval to sell a generic version, according to the proposed consent judgment filed Thursday. The judgment would also have InvaGen promise not to make or sell the proposed...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!